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1 Chapter 4 
 
Table 4.1. Patterns of gene expression regulation that were stimulated by R848 and/or TNFa. 
Up and down indicates upregulation and downregulation respectively, while No designates no 
differential regulation of gene expression. UT=no treatment, R= R848, T= TNFa and 
RT=R848+TNFa. 2-fold change cut off was applied to determine differential expression 
compared to unstimulated neutrophils. The following tables mention the members of each 
group of genes related to a particular pattern of transcription regulation indicated in this table. 
They are presented in the same order of their appearance in this table. 
 
No. of genes R/UT T/UT RT/UT Comments Pattern of regulation in RT 
38 Up/No Up/No Up RT>R+T Synergistic upregulation 
14 Up Up Up RT=R+T Additive upregulation 
235 Up Up Up RT=R, RT>T Upregulatory effect dominated by 
R 
33 Up Up Up RT=T, RT>R Upregulatory effect dominated by T 
22 Up Up Up RT=R, RT<T R prevented further induction by T 
4 Up Up Up RT<T, RT>R R partially prevented further 
induction by T 
19 Up Up Up RT=T, RT<R T prevented further induction by R 
14 Up No No  T stopped R-mediated upregulation 
5 Up No Up RT<R T partially stopped R-mediated 
upregulation 
3 Up Up No  R and T had different combined 
effect to their individual effects 
43 No Up No  R completely inhibited 
upregulatory effect of T  
9 No Up Up RT<T R partially inhibited upregulatory 
effect of T 
5 Down Up Down RT<T, RT=R Downregulatory effect due to R 
alone 
38 Up Down Up RT=R R masked or prevented T effect and 
increased gene expression 
42 No Down No RT=R R prevented T effect  
12 Down Down Down RT=R, RT>T R stopped further down regulation 
by T 
37 Down Down Down RT<R, RT<T Additive inhibition 
393 Down  Down Down RT=R, RT<T R masked or dominated T effect 
25 Down Down Down RT>R, RT£T T partially stopped downregulatory 
effect of R 
8 Down Down Down RT=T, RT<R T masked or dominated R effect 
12 Down No Down RT>R, RT<T T partially stopped downregulatory 
effect of R 
16 Down No Down RT=T T completely stopped 
downregulatory effect of R 
212 No  No Down  Only dual action of R and T 
reduced expression level in U  
 
  
 2 
Table 4.2. Genes synergistically upregulated by R848+TNFa. Molecule types, FPKMs associated 
with no treatment (UT), R848, TNFa and R848+TNFa treatments, and calculated synergy ratios were 
indicated.  
Gene Molecule type UTFPKM R848FPKM TNFaFPKM 
R848 + 
TNFaFPKM 
Ratio 
IL6 
Cytokine 
0.16 112.85 0.49 194.77 1.72 
IL12B 0.36 15.14 1.38 29.24 1.73 
IL23A 0.12 17.60 5.60 56.34 2.42 
IL27 0.25 1.68 0.64 4.52 1.76 
IL36G 0.03 6.00 0.28 22.47 3.56 
TNFSF9 0.01 0.51 0.15 5.00 7.34 
CXCL10 0.04 13.41 1.20 18.69 1.28 
CSF3 0.05 40.06 1.10 86.72 2.10 
SOCS3 
Enzyme 
15.55 65.11 13.68 142.17 1.51 
CARD17 0.68 14.50 8.15 30.53 1.31 
CD274 0.71 107.52 18.88 164.87 1.30 
DHX58 1.83 71.15 2.58 101.52 1.34 
PTGS2 15.77 164.76 60.51 321.33 1.33 
LSS 0.20 15.13 12.62 39.44 1.41 
B3GNT7 0.17 1.61 0.58 4.32 1.84 
CASP5 1.12 18.82 5.77 39.44 1.53 
MAP3K8 20.79 454.74 143.66 967.87 1.56 
PTX3 
Receptor 
0.09 4.42 2.26 12.87 1.90 
NR4A1 0.31 5.67 6.48 15.97 1.28 
P2RX4 1.44 11.74 5.58 23.66 1.26 
SEMA6A 0.05 4.72 0.75 8.11 1.47 
SLAMF7 2.09 273.49 72.49 535.78 1.54 
CD200 
Membrane-
associated protein 
0.02 1.18 0.45 3.07 1.86 
FAM57A 0.03 1.15 1.45 5.88 2.24 
COL17A1 0.05 1.65 0.90 5.38 2.07 
FLVCR2 0.12 0.92 0.52 3.26 2.08 
IFT57 
Transcription 
factor 
0.77 7.37 3.00 15.51 1.39 
BATF 1.95 20.23 5.21 40.19 1.47 
STAT5A 23.80 63.10 94.90 267.08 1.47 
FOXP1 3.14 3.36 1.44 13.82 1.74 
CFB Complement factor 0.01 2.98 1.48 9.07 2.03 
TRIP10 
Signal transducer 
0.35 17.90 19.35 50.13 1.33 
TRAF4 0.26 6.56 1.21 16.41 2.04 
PI3 
Inhibitor 
28.47 7373.06 2969.67 15368.90 1.48 
SERPINB2 0.24 11.71 2.76 20.36 1.38 
SPINK1 1.89 16.40 9.36 38.86 1.41 
EIF3CL Translation factor 0.00 0.00 0.00 3.29 907.10 
SMG9 mRNA decay factor 2.43 25.18 11.91 52.73 1.33 
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Table 4.3. List of 14 TNFa/R848-upregulated genes that were additively induced by the effect of R848 
and TNFa. 2-fold change cut off was applied to determine differential expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ABTB2 0.62 2.12 1.91 4.62 
BCL2L1 6.34 18.77 16.50 43.94 
DNAJB5 0.99 4.80 4.23 10.62 
LOC100499177 7.42 20.07 12.20 40.19 
MGLL 1.78 18.14 20.01 41.80 
PHF19 1.21 7.44 6.37 16.55 
RASGRP1 0.30 2.77 2.69 6.55 
RHBDF2 2.17 45.07 35.15 96.32 
SLC24A1 0.14 5.41 4.49 11.57 
SMG7 17.96 27.86 36.08 72.39 
TMEM106A 1.12 4.65 3.07 10.17 
TMEM38B 0.34 1.55 1.02 3.25 
TNFAIP8 18.37 41.91 64.93 134.67 
TSEN15 0.21 1.10 0.94 2.60 
 
 
Table 4.4. A selection of TNFa-stimulated genes (235 in total) that were further stimulated by treatment 
with R848 and TNFa. The additional induction of gene expression was comparable to R848 effect alone 
indicating that R848 dominated the effect of TNFa. 2-fold change cut off was applied to determine 
differential expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ADA 0.98 28.57 11.93 31.06 
ARL8B 23.15 107.96 55.24 112.11 
C3 0.99 109.81 54.47 111.55 
CCL4L2 55.20 7583.38 2512.90 7752.05 
CCRL2 28.21 949.51 388.64 1010.01 
FXYD6 0.75 23.63 6.71 24.43 
G0S2 87.44 3277.50 1687.38 3527.76 
GK 42.19 367.17 176.23 378.19 
HCAR3 12.92 235.67 89.87 258.33 
MAPK6 2.88 73.06 32.10 79.73 
MOB3C 4.28 42.68 17.24 46.10 
MORF4L2 9.12 42.92 19.64 43.42 
PLEK 163.16 1913.05 766.41 2011.78 
SLC5A5 2.31 13.55 5.98 14.24 
SLC7A11 2.42 12.14 6.20 12.75 
STAT4 1.03 29.38 10.69 29.52 
TMEM123 54.57 364.77 112.69 367.27 
TNF 3.63 431.70 136.16 445.41 
WSB1 68.66 364.66 183.30 390.88 
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Table 4.5. A list of some TNFa/R848-stimulated genes (33 in total) that were further stimulated by the 
treatment with R848 and TNFa. However, the additional induction of gene expression was comparable 
to TNFa effect alone indicating that TNFa dominated the effect of TNFa. The fold change cut off for 
expression data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
C8orf38 0.18 1.42 4.23 4.22 
CD40 0.01 2.85 10.08 10.60 
CLEC4D 2.96 11.55 24.25 23.85 
DHRS13 6.32 18.69 53.82 47.41 
DNAJC3 16.32 48.37 87.75 105.31 
DUSP2 7.21 104.67 181.26 224.13 
LRRC8D 2.34 5.08 11.18 14.06 
ORM1 2.13 199.01 342.09 407.96 
ORM2 1.52 70.27 127.67 151.74 
PSTPIP2 4.62 17.70 45.84 47.52 
TNFRSF4 0.22 2.29 4.75 5.74 
WNT5B 0.20 1.97 5.92 6.27 
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Table 4.6. List of 22 TNFa-stimulated genes that were also upregulated, but to less extent by R848 
alone. The combined treatment with R848 and TNFa was comparable to the effect of R848 alone 
indicating that R848 prevented their further induction by TNFa. 2-fold change cut off was applied to 
determine differential expression. 
  
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
CCDC134 1.23 3.23 6.92 1.96 
CTSH 3.37 20.94 53.33 22.22 
FAM110A 12.03 34.15 64.71 27.46 
GHRL 8.98 24.95 48.64 18.71 
GHRLOS 1.77 5.26 8.43 3.66 
GPR35 0.20 2.78 6.14 1.77 
GYPC 3.42 7.43 14.02 6.24 
LOC389634 2.20 10.01 41.05 17.86 
LRP5L 1.03 3.50 9.03 4.34 
PHB 1.25 5.33 10.39 3.78 
PLEC 3.32 12.45 24.71 12.32 
PRDX1 3.80 21.72 33.21 13.99 
PRPSAP1 2.56 22.77 40.91 19.18 
SLC1A5 1.88 6.49 15.42 5.37 
SLC25A39 1.40 4.64 6.81 3.40 
SMPD2 4.38 10.67 23.80 9.22 
TMEM205 5.52 35.53 87.78 35.69 
TRAF2 1.22 2.85 5.95 2.52 
AKR1A1 7.03 15.68 36.81 9.23 
ANKRD22 0.77 3.66 8.57 1.88 
CCL3L3 0.65 141.49 186.16 71.80 
SPATC1 0.11 19.16 28.14 10.62 
 
Table 4.7. List of TNFa-stimulated genes that were also upregulated, but to less extent, by R848 alone. 
The combined treatment with R848 and TNFa was lower than that induced by TNFa, but higher than 
R848-induced expression. Hence, R848 partially prevented their further induction by TNFa. 2-fold 
change cut off was applied to determine differential expression. 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
C21orf67 0.57 1.93 10.22 4.12 
FAM125B 0.10 0.52 3.62 1.52 
FSCN1 2.55 12.48 113.69 45.90 
LMNB2 0.49 1.03 7.60 3.56 
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Table 4.8. 19 R848/TNFa-stimulated genes that were downregulated when neutrophils were 
additionally treated with TNFa compared to untreated cells. TNFa stopped their maximum induction 
by R848. The fold change cut off for expression data was 2-fold in both directions. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ASB2 0.19 6.66 1.41 1.30 
C19orf59 25.02 196.28 82.95 54.75 
C1orf106 0.19 2.83 2.34 1.26 
CDKN1A 7.97 906.56 290.85 372.75 
EXOSC4 1.29 24.45 12.55 12.18 
FAM83G 0.15 1.05 0.46 0.39 
GPR4 0.39 2.35 0.99 0.78 
HIVEP3 0.20 1.35 0.91 0.46 
KCNH4 2.51 35.09 30.75 16.51 
KIFC3 2.61 11.78 9.35 4.97 
LACC1 0.53 29.71 16.35 14.65 
NEDD4 0.61 3.27 2.48 1.40 
PNP 1.75 10.42 4.30 4.96 
PRR5L 19.79 121.75 54.70 53.33 
TACSTD2 2.01 9.10 7.20 4.02 
TNFRSF10D 1.06 8.38 4.58 3.49 
TRIB3 0.61 5.57 2.02 2.68 
CHMP7 5.58 12.33 10.15 5.64 
SLC22A18AS 1.40 7.98 2.77 3.90 
  
Table 4.9. 14 R848-stimulated genes that were downregulated to basal level in in untreated cells when 
neutrophils were additionally treated with TNFa. TNFa alone had no effect on these genes, hence 
TNFa prevented R848-mediated induction of gene expression. The fold change cut off for expression 
data was 2-fold in both directions. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
FAM27C 0.44 1.02 0.33 0.38 
FAM54A 0.59 1.61 0.83 0.57 
GSTT1 0.92 2.08 1.46 0.97 
HPSE 26.95 95.75 24.18 33.39 
INPP1 2.02 4.29 1.53 1.75 
LIF 1.28 6.17 1.38 2.63 
P2RY2 4.19 14.49 6.46 5.84 
P2RY6 0.73 5.59 0.98 1.52 
RALGAPA1 9.20 27.31 13.94 11.64 
RPL21 0.05 19.76 0.06 0.07 
SPRED2 2.27 5.79 3.43 2.55 
TGM2 12.50 113.24 12.04 13.29 
TMEM126A 0.89 2.18 0.91 0.82 
TRMT6 0.43 1.88 0.76 0.70 
 7 
Table 4.10. List of R848-stimulated genes that were downregulated when neutrophils were additionally 
treated with TNFa. TNFa partially stopped their maximum induction by R848. The fold change cut off 
for expression data was 2-fold in both directions. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
C1orf189 1.24 7.19 1.48 3.16 
CD69 1.78 327.41 47.00 159.56 
CKAP2L 0.17 7.67 1.30 3.50 
CXCL1 96.22 587.14 91.83 226.30 
FAP 0.18 10.39 0.88 5.07 
 
Table 4.11. List of TNFa/R848-stimulated genes that were downregulated to basal level in untreated 
cells when neutrophils were treated with R848 and TNFa indicating that R848 and TNFa had a 
different combined effect to their solo actions. 2-fold change cut off was applied to determine 
differential expression. 
  
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
CYP1B1 1.06 5.05 5.02 2.36 
LRG1 39.01 107.88 128.55 47.46 
SEMA6B 18.13 47.58 63.14 19.95 
 
Table 4.12. List of TNFa-stimulated genes (43 in total) that were downregulated when neutrophils 
were treated with R848 prior to TNFa. R848 alone did not regulate the expression of these genes, but 
it completely inhibited their TNFa-induced expression. 2-fold change cut off was applied to determine 
differential expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
B9D2 6.97 9.26 14.82 6.91 
CGRRF1 1.90 2.51 4.12 1.95 
COMMD3 8.00 8.80 17.53 6.51 
FHOD1 35.67 39.55 76.17 37.66 
GALNS 7.73 9.78 17.26 8.33 
GPR137 2.48 2.70 6.09 2.50 
GSTP1 2.02 2.23 4.85 1.68 
PDE6D 5.09 6.40 10.25 4.31 
PLIN5 5.86 9.65 11.75 5.54 
RPIA 1.10 1.12 2.40 1.14 
VPS37C 16.46 17.41 33.82 15.54 
ZNF385A 3.53 4.74 14.21 3.94 
CECR6 1.42 1.01 3.23 1.51 
ETFB 5.44 5.35 14.06 6.21 
NRSN1 1.08 0.92 2.58 1.26 
PNKD 14.87 11.63 38.60 12.68 
TNFAIP8L1 8.35 7.96 21.01 6.73 
TNFRSF10B 59.33 54.15 122.80 61.13 
ZNF281 8.68 6.79 24.17 7.30 
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Table 4.13. List of 9 TNFa-stimulated genes that were downregulated when neutrophils were treated 
with R848 prior to TNFa. R848 alone did not regulate the expression of these genes, but it partially 
inhibited their TNFa-induced expression. 2-fold change cut off was applied to determine differential 
expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
C6orf97 0.52 1.00 3.95 1.88 
CDC14B 0.11 0.16 2.87 0.41 
CDKN2C 0.35 0.39 3.44 1.44 
GPX1 15.84 19.37 73.51 32.79 
MAN1A1 7.61 14.14 48.32 17.48 
NR6A1 1.93 2.59 11.14 4.44 
TBC1D2B 11.62 23.10 63.65 29.92 
TESK1 1.46 1.85 6.72 3.29 
INO80B 0.36 0.27 5.38 2.04 
 
Table 4.14. List of TNFa-stimulated genes that were downregulated by the treatment with R848 and 
TNFa. This downregulatory effect was due to R848 since R848 alone reduced the expression of these 
genes.  2-fold change cut off was applied to determine differential expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
GSN 75.93 34.15 157.58 46.98 
LRRC61 1.61 0.55 4.34 1.37 
PGLYRP1 8.02 3.88 18.39 3.21 
RMRP 1.17 0.32 16.44 1.07 
TICAM2 2.59 1.11 5.63 2.67 
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Table 4.15. List of selected TNFa-downregulated genes that were upregulated when neutrophils were 
treated with R848 and TNFa. The combined effect was comparable to that observed with R848 
treatment indicating that R848 masked or prevented  the downregulatory effect of TNFa. The genes 
were grouped based on R848 solo effect on their expression compared to no treatment. Number of genes 
is (38 and  42 and 12 respectively). 2-fold change cut off was applied to determine differential 
expression. 
 
Gene R848 effect UTFPKM R848FPKM TNFaFPKM 
R848 + 
TNFaFPKM 
IFI44 
Upregulation (IFN-
response genes) 
4.44 147.60 1.38 128.70 
IFI44L 1.65 48.86 0.68 41.16 
IFIT1 23.46 1249.30 7.63 1034.36 
IFIT2 211.35 2279.85 42.66 2028.77 
IFIT5 14.12 265.22 6.75 233.89 
LY6E 3.82 35.49 1.42 29.85 
MT2A 12.77 241.92 3.33 289.28 
OAS1 5.04 109.77 1.93 95.40 
OASL 21.35 222.58 4.00 196.72 
PARP12 10.09 101.55 4.23 102.99 
SP110 63.29 248.17 30.32 216.06 
SP140 23.68 60.10 9.31 61.72 
SP140L 8.97 34.97 4.40 32.26 
TNFSF10 38.60 152.36 4.64 132.24 
TRIM22 44.82 499.28 13.86 506.20 
TRIM25 9.72 53.71 3.64 53.00 
ZBP1 36.72 141.35 11.23 135.06 
DYNLT1  66.68 80.61 31.63 66.34 
MIA3  12.57 15.95 5.38 13.11 
NT5C2 No regulation 73.19 71.81 30.17 75.68 
PTP4A1  35.96 41.01 13.03 41.96 
RNF138  12.31 10.78 4.41 9.77 
TNK2  15.27 17.87 5.55 20.39 
DYNLT1  66.68 80.61 31.63 66.34 
HAUS4  30.42 8.98 3.39 7.05 
PFKFB4  7.17 1.73 0.54 2.61 
SLC30A1 Downregulation 7.97 1.83 0.79 1.74 
TBC1D1  10.28 5.02 2.94 6.44 
THBD  25.23 3.82 1.38 3.07 
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Table 4.16. List of 22 TNFa-downregulated genes ( that were additively inhibited by the combined 
effect of R848 and TNFa. a. 2-fold change cut off was applied to determine differential expression. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
C18orf1 2.60 1.91 1.11 0.53 
CAMKK1 24.71 3.72 6.86 1.42 
CEACAM21 18.76 2.74 4.74 1.26 
DEF6 58.67 13.72 15.58 6.30 
EBPL 2.67 1.04 0.91 0.29 
ENC1 34.87 17.22 12.97 3.16 
EPOR 6.66 0.91 1.07 0.43 
FAM211A 23.42 1.63 4.49 0.21 
HIST1H4E 4.51 0.91 1.68 0.35 
LYL1 33.89 4.39 5.66 1.31 
MBD4 29.76 8.69 9.29 4.11 
MSRB2 3.85 1.58 1.63 0.71 
NLRP12 30.46 15.27 14.83 6.84 
OGFOD2 2.39 0.64 0.96 0.23 
OPRL1 7.56 0.76 2.38 0.36 
POLR3K 10.17 0.63 0.87 0.18 
PPP1R3D 17.49 4.57 6.03 2.03 
SLC25A20 7.13 0.96 1.06 0.46 
SNAI1 3.43 1.41 0.84 0.23 
STAU2 3.32 1.08 0.82 0.36 
TM6SF1 78.77 18.51 23.08 6.24 
TMEM101 3.68 1.09 1.16 0.52 
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Table 4.17. List of some TNFa-downregulated genes (393 in total) that were further inhibited by 
treatment with R848 and TNFa. The joined influence of R848 and TNFa was comparable to R848-
downregulatory effect which indicates that R848 masked the effect of TNFa. The fold change cut off 
for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ABHD5 52.20 7.22 16.18 7.88 
AKT1 73.01 10.98 23.62 9.21 
ARHGDIB 666.05 103.16 270.73 109.22 
CTDSP2 112.17 23.70 54.11 26.91 
CXCR1 362.03 14.29 38.75 13.18 
CXCR2 665.42 31.11 92.81 31.40 
EPB41 69.07 6.76 17.26 7.09 
FCHO2 25.05 3.79 10.34 3.84 
FURIN 73.06 17.49 34.56 15.19 
H2AFV 32.97 9.10 15.73 7.48 
HOTAIRM1 59.81 5.41 11.46 4.80 
LIMD2 103.59 10.10 38.44 9.02 
LMBRD1 80.09 12.41 27.35 13.48 
LOC285074 26.56 4.85 12.75 5.69 
MAP2K4 37.09 7.07 18.50 7.64 
MAPK3 36.20 5.82 12.34 4.93 
MYADM 98.94 16.77 46.60 14.55 
NUAK2 58.24 3.96 18.11 4.54 
ORAI3 24.74 5.85 11.00 4.90 
OTUD1 36.63 6.10 13.74 6.49 
PHOSPHO1 113.45 1.86 13.95 1.56 
PYCARD 98.70 14.88 36.13 12.67 
RAB11FIP4 39.09 6.30 11.66 5.21 
RAB3D 64.01 4.70 16.56 4.22 
RNPEP 38.42 8.37 15.88 7.51 
SELPLG 111.40 3.12 11.61 2.61 
SLC9A3R1 50.84 3.90 11.16 4.15 
STK38L 40.26 8.44 17.54 8.59 
TBC1D10C 51.50 2.83 10.56 2.53 
TNFRSF10C 238.85 26.34 81.30 31.08 
TUBA1A 48.38 5.68 12.50 4.83 
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Table 4.18. A list of 25 R848-downregulated genes that were also downregulated, but to less extent, 
by TNFa alone. TNFa appeared to partially stop the downregulatory effect of R848 since the combined 
effect of R848 and TNFa was comparable to or less than that induced by TNFa alone. The fold change 
cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
AMICA1 175.66 21.92 84.95 65.14 
CDC42EP4 2.86 0.60 1.42 1.56 
CERKL 4.47 0.37 0.58 0.85 
CISH 2.35 0.76 1.13 1.94 
CLEC9A 2.06 0.16 0.21 0.40 
EGLN1 22.87 0.75 2.97 1.59 
FAM45B 7.17 0.18 0.46 0.52 
GLRX5 4.17 0.56 1.04 1.15 
GPR27 2.69 0.17 0.47 0.44 
GRAMD1C 11.36 0.69 3.31 1.78 
HIST1H4D 4.23 0.17 0.71 1.15 
HIST4H4 3.76 0.12 1.43 0.99 
HLA-DMB 3.74 0.17 0.93 0.63 
JARID2 54.48 5.72 13.98 12.60 
KDM3A 38.44 8.17 18.03 22.85 
MME 30.77 5.59 7.23 11.66 
MYO18A 8.11 0.73 1.08 1.62 
NFXL1 3.04 0.32 1.06 1.10 
NMRAL1 3.66 0.11 0.25 0.34 
PMF1 6.33 1.00 2.20 2.10 
RAVER1 16.91 3.10 7.12 6.90 
RGS2 742.35 72.00 176.34 188.35 
SELO 11.57 0.88 2.86 1.96 
TUBGCP3 9.14 0.82 3.78 1.90 
ZNF362 3.93 0.07 0.24 0.28 
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Table 4.19. List of R848-downregulated genes that were further repressed by the combined effect of 
R848 and TNFa. R848 and TNFa together exhibited an inhibitory effect comparable to that induced 
by TNFa alone indicating that R848 effect was masked by TNFa. The fold change cut off for 
expression data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ABAT 7.95 2.06 1.28 1.02 
CDKN1C 2.73 1.01 0.59 0.48 
MAP7 3.98 1.62 0.95 0.73 
PCNA-AS1 9.53 3.58 1.80 1.27 
PMM1 2.99 0.39 0.22 0.18 
PRKDC 23.83 6.83 4.35 3.22 
TXN2 9.07 3.98 2.94 1.96 
VKORC1L1 3.08 1.17 0.56 0.57 
 
Table 4.20. 12 R848-downregulated genes that were not affected by TNFa alone. TNFa appeared to 
partially stop the downregulatory effect of R848. The fold change cut off for expression data was 2-
fold. 
 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
BCORL1 2.56 0.33 2.08 0.99 
CABIN1 3.72 0.41 2.31 0.82 
DPM3 4.00 0.51 2.50 1.17 
ELMO2 8.24 2.44 11.90 5.04 
NAB2 3.13 0.32 1.93 0.72 
SORD 4.39 0.91 6.22 2.09 
CBX1 5.80 0.62 3.04 1.59 
IGFLR1 17.90 3.03 12.28 6.19 
KLF7 15.26 4.27 24.11 13.86 
LOC100505746 18.26 5.93 25.88 13.56 
PPP1R9B 67.24 24.09 114.10 62.37 
WHSC1L1 14.94 2.45 9.83 4.94 
 
  
 14 
Table 4.21. A list of 16 R848-downregulated genes that were not affected by TNFa alone. TNFa 
appeared to completely stop the downregulatory effect of R848. The fold change cut off for expression 
data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
BAZ2A 43.49 14.76 28.08 31.24 
CBFA2T3 3.15 0.76 3.66 5.63 
CDC42SE2 92.21 42.52 87.78 88.18 
FUT11 2.62 1.09 2.09 2.49 
GTF2IP1 34.67 5.87 21.39 17.12 
ITPKB 19.25 3.40 11.24 7.78 
MAP3K5 12.50 5.91 9.61 19.01 
NDUFA7 2.95 1.47 2.61 3.11 
NFATC1 2.72 1.12 3.15 2.54 
P2RY10 14.82 2.55 10.17 6.64 
PHF12 38.92 10.13 39.72 31.99 
STARD5 19.70 4.41 13.59 9.45 
STAT5B 63.71 29.24 63.42 92.94 
TP53INP1 110.33 18.60 67.81 54.22 
TXNDC16 3.70 1.50 1.88 3.01 
ZMYND8 4.35 0.92 3.13 2.36 
 
Table 4.22. List of selected genes (212 in total) that were not differentially regulated by R848 or TNFa. 
However, the combined treatment with R848 and TNFa reduced their expression. The fold change cut 
off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM TNFaFPKM R848 + TNFaFPKM 
ARPC4 151.13 156.60 149.17 0.00 
BPGM 13.80 13.55 12.32 5.85 
C11orf31 8.37 6.61 8.00 3.91 
CBFB 21.434 15.7673 15.8374 10.3837 
CMTM3 15.80 15.05 17.83 7.61 
DNAJA2 24.0494 22.6736 17.5616 11.6195 
DNAJB14 18.6717 13.7166 14.4425 9.31058 
DNAJC4 6.21 4.74 4.79 2.91 
ELOF1 11.3922 8.06313 8.38527 5.6492 
NUTF2 6.24 5.04 7.16 2.95 
RGS19 107.174 75.086 86.665 36.2856 
SF3A3 7.17344 5.74644 5.22519 2.22759 
ST3GAL6 36.9171 26.8808 32.0108 15.4937 
TLR1 99.2803 72.2701 84.2254 44.536 
TTLL3 5.20 4.80 4.66 0.00 
ZMAT5 15.7646 14.3698 11.2915 7.55661 
 
  
 15 
Table 4.23. Patterns of gene expression regulation stimulated by R848 and/or GM-CSF. Up 
and down indicates upregulation and downregulation respectively, while No designates no 
differential regulation of gene expression. UT=no treatment, R= R848, G= GM-CSF and 
RG=R848+GM-CSF. 2-fold change cut off was applied to determine differential expression 
compared to unstimulated neutrophils. The following tables mention the members of each 
group of genes related to a particular pattern of transcription regulation indicated in this table. 
They are presented in the same order of their appearance in this table. 
No. of 
genes R/UT G/UT RG/UT Comments Possible pattern of regulation in RG 
91 Up/No Up/No Up RG>R+G Synergistic upregulation 
243 Up Up Up RG=R+G Additive upregulation 
19 Up Up Up RG=R, 
RG<G 
R prevented further induction by G 
18 Up Up Up RG>G, 
RG<R 
G partially prevented further 
induction by R 
11 Up Up Up RG=G, 
RG<R 
G prevented further induction by R 
248 Up No Up RG<R G partially stopped R-mediated 
upregulation 
5 Up Up No  R and G had different combined 
effect to their individual effects 
129 No Up No  R completely inhibited 
upregulatory effect of G  
47 No Up Up RG<G R partially inhibited upregulatory 
effect of G 
7 Down Up Up RG<G R partially inhibited upregulatory 
effect of G 
12 Down  Up Up RG=G G stopped the downregulatory 
effect of R 
68 Down Up No  R completely inhibited 
upregulatory effect of G 
69 Down Up Down RG<G RG³R Downregulatory effect due to R 
alone to inhibit G effect 
15 Up Down  Up RG<R G partially inhibited upregulatory 
effect of R  
9 Up Down Up RG=R R masked or prevented G effect and 
increased gene expression  
32 Up Down No  G completely inhibited 
upregulatory effect of R  
28 No Down No RG=R R prevented G effect  
136 Down Down Down RG<R, 
RG<G 
Additive inhibition 
9 No Down Down RG<G R further induced G effect 
165 Down  Down Down RG=R, 
RG<G R masked or dominated G effect 
18 Up Down Down RG=G, 
RG<G 
G inhibited upregulatory effect of R 
and reduced basal level in UT 
56 Down No No  G completely stopped 
downregulatory effect of R 
46 Down Down Down RG=G, 
RG<R G masked or dominated R effect 
30 Down No Down RG>R, 
RG<G 
G partially stopped downregulatory 
effect of R 
 16 
No. of 
genes R/UT G/UT RG/UT Comments Possible pattern of regulation in RG 
91 Down No Down RG<R G enhanced downregulatory effect 
of R  
2 Down Down Down RG=G, 
RG>R 
G inhibited further downregulation 
by R 
397 No  No Down  Only dual action of R and G 
reduced expression level in UT  
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Table 4.24. Genes synergistically upregulated by R848+GM-CSF. Molecule types, FPKMs 
associated with no treatment (UT), R848, GM-CSF and R848+GM-CSF treatments, and calculated 
synergy ratios were shown. 
 
Gene Molecule type UTFPKM R848FPKM 
GM-
CSFFPKM 
R848 + GM-
CSFFPKM 
Ratio 
CCL3 
Cytokine 
6.32 4704.98 53.59 9150.95 1.92 
CCL3L1 14.40 1119.18 50.85 1448.68 1.22 
CCL3L3 0.65 141.49 16.69 1195.45 7.53 
CCL4 24.92 7463.63 121.76 10745.30 1.41 
CCL4L2 55.20 7583.38 288.87 12567.30 1.59 
CXCL2 5.04 112.72 13.30 172.59 1.32 
CXCL3 1.08 9.97 2.57 16.47 1.21 
IL1A 0.81 598.91 20.84 1516.00 2.44 
IL1B 39.54 7529.71 353.23 13302.00 1.68 
IL1RN 12.98 2426.58 2199.81 6532.34 1.41 
IL36G 0.03 6.00 0.02 31.63 5.23 
IL6 0.16 112.85 0.33 140.40 1.24 
IL8 1602.37 30540.10 6931.77 49146.40 1.26 
TNF 3.63 431.70 57.51 901.46 1.83 
TNFSF15 0.75 9.61 3.35 31.97 2.33 
AEN 
Enzyme 
0.28 1.52 1.88 13.03 3.54 
ATP2C2 3.84 12.23 5.66 32.00 1.47 
CARKD 0.81 1.66 2.40 6.12 1.26 
CASP10 2.61 6.13 8.66 20.99 1.21 
CASP5 1.12 18.82 5.12 48.39 1.93 
CES1 0.52 5.59 2.26 19.73 2.36 
DDX21 2.58 15.79 30.23 119.11 2.45 
DDX47 1.69 1.01 1.45 6.48 1.56 
DOT1L 0.91 17.32 5.68 28.89 1.21 
ECE2 0.02 0.06 0.93 13.86 13.61 
NDUFV2 12.38 80.28 104.00 496.34 2.52 
PRDM7 0.25 2.34 0.31 7.37 2.55 
RDH13 0.89 3.70 1.38 10.28 1.72 
RHOH 1.89 14.53 100.72 279.75 2.39 
RNF175 0.33 6.64 3.17 18.63 1.84 
SOCS3 15.55 65.11 257.06 754.64 2.23 
TARP 0.93 1.47 11.11 39.72 2.94 
TRIB3 0.61 5.57 3.21 17.96 1.91 
TXN 50.17 194.65 457.84 846.49 1.20 
UPP1 4.40 24.19 186.02 272.17 1.27 
USP36 0.97 2.27 3.86 9.34 1.32 
GNL2 GTPase 1.99 3.45 4.98 17.21 1.65 
 18 
Gene Molecule type UTFPKM R848FPKM 
GM-
CSFFPKM 
R848 + GM-
CSFFPKM 
Ratio 
GNL3 0.49 0.97 2.33 5.09 1.34 
GTPBP4 0.74 2.81 12.53 23.17 1.44 
NOLC1 1.12 3.45 3.75 15.02 1.81 
RHOU 0.12 16.25 0.86 45.07 2.62 
CFLAR Enzyme 
regulator 
75.94 286.59 192.55 714.49 1.29 
PPP1R15A 50.41 851.04 109.62 1325.18 1.31 
CD40 
Receptor 
0.01 2.85 0.22 7.56 2.44 
CD44 62.09 1050.03 945.92 2524.10 1.23 
CD48 15.66 352.33 38.18 577.42 1.42 
SLAMF1 0.14 2.58 0.54 65.06 19.95 
HRH1 0.29 6.55 0.63 11.23 1.50 
P2RX4 1.44 11.74 4.34 48.57 2.77 
SDC4 0.02 0.85 0.26 7.09 6.31 
TFRC 1.19 32.83 3.55 46.17 1.23 
TLR2 14.49 237.30 215.56 941.23 2.01 
PTX3 0.09 4.42 1.25 11.46 1.99 
CCND2 
Cell cycle 
regulator 
2.56 0.66 18.65 52.71 2.41 
CCNE2 1.00 1.04 6.87 31.97 3.59 
CDK4 1.22 2.55 3.66 11.83 1.59 
DNTTIP2 
Transcription 
regulator 
12.21 79.82 48.83 186.67 1.33 
C6orf108 0.35 4.34 0.33 8.32 1.66 
EGR3 0.69 39.48 15.14 72.12 1.30 
ELK1 1.78 7.53 3.40 18.97 1.49 
ETS2 20.75 200.95 303.75 674.40 1.28 
EYA3 6.51 33.12 31.97 87.80 1.23 
FOSL1 0.17 5.09 1.95 15.69 2.18 
IFT57 0.77 7.37 0.63 11.77 1.34 
MAFF 7.94 270.87 79.53 487.12 1.36 
NR1D1 1.19 8.49 4.13 18.46 1.34 
ABCF1 
Translation 
initiation 
factor 
5.20 20.55 16.32 56.82 1.35 
EIF1B 53.68 236.16 304.92 745.91 1.25 
EIF3I 4.98 10.28 13.37 36.59 1.28 
EIF4A1 21.90 64.63 89.72 251.60 1.43 
TRMT6 0.43 1.88 3.62 12.97 2.19 
B7H6 
Structural 
molecule 
0.50 34.77 1.95 62.66 1.68 
MRPL14 0.30 4.70 1.15 11.38 1.85 
MRPL52 1.97 19.69 2.44 36.63 1.52 
MRPS24 1.10 10.43 2.63 19.03 1.34 
PI3 
Inhibitor 
28.47 7373.06 240.17 16353.10 2.14 
SERPINB2 0.24 11.71 0.91 24.82 1.93 
 19 
Gene Molecule type UTFPKM R848FPKM 
GM-
CSFFPKM 
R848 + GM-
CSFFPKM 
Ratio 
SPINK1 1.89 16.40 17.14 46.95 1.32 
SPINT2 5.52 61.78 124.21 278.85 1.46 
SLC25A33 
Transporter 
0.71 2.70 2.98 11.35 1.77 
SLCO4A1 0.61 11.60 0.88 19.94 1.52 
EDN1 Hormone 0.57 5.15 2.31 48.73 6.06 
F3 Coagulation factor 0.85 30.72 1.60 48.55 1.46 
GJB2 Junction Channel 0.27 8.51 0.14 13.80 1.55 
HBEGF Growth factor 0.36 0.65 17.78 63.96 3.40 
HSPA9 Heat shock protein 4.53 9.26 16.70 43.59 1.43 
UBQLN4 Proteasomal ubiquilin 0.67 1.95 1.06 12.25 3.33 
RPF2 rRNA binding 0.09 2.39 1.51 15.62 3.92 
TRAF1 Signal transducer 0.73 273.02 2.28 421.43 1.53 
COMMD4 Other 2.43 9.22 5.54 27.72 1.61 
 
Table 4.25. A selection of GM-CSF-upregulated genes that were additively induced by R848 
effect (243 genes). The fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
AZIN1 34.64 389.25 97.77 493.22 
CREM 21.12 65.04 49.95 128.68 
EIF1 156.90 544.42 573.28 1260.22 
FPR2 201.72 736.18 810.62 1675.96 
GLA 19.97 80.66 41.85 142.25 
GNG2 30.69 677.51 80.10 762.68 
MAPK6 2.88 73.06 8.30 82.27 
NFKBIZ 14.12 774.06 61.80 823.24 
OLIG1 0.61 13.53 6.78 20.58 
PIM3 32.78 359.94 212.34 571.99 
PLAU 43.59 1397.04 233.17 1649.84 
RBM17 3.52 24.61 11.36 38.25 
SAMSN1 17.41 610.02 68.98 693.21 
SERPINB8 7.71 107.14 17.76 127.87 
TREML3 6.55 23.65 27.38 55.73 
TRPM2 2.58 24.30 6.65 32.44 
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Table 4.26. List of 19 GM-CSF-upregulated genes that were downregulated by the addition of 
R848 although R848 alone induced their expression. The expression level of the genes in 
response to R848 and GM-CSF was comparable to or slightly lower than that induced by R848 
alone indicating that R848 possibly inhibited further induction of expression by GM-CSF. The 
fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ABP1 1.08 7.13 14.46 4.40 
ANKRD22 0.77 3.66 80.92 1.96 
CBWD3 1.34 2.69 5.52 2.43 
CBWD6 0.62 1.33 2.82 1.20 
CD97 63.72 131.68 624.79 236.55 
DUSP6 20.25 109.80 383.40 147.63 
FAM65B 21.68 63.51 236.88 101.67 
HLA-DQB1 9.98 36.48 89.79 39.53 
HLA-DQB2 0.32 1.07 4.12 1.11 
IL18R1 2.80 7.29 29.73 6.18 
IL1R2 44.35 163.41 635.04 191.71 
LRG1 39.01 107.88 300.75 119.11 
POLA2 1.09 3.77 7.70 3.81 
SEMA6B 18.13 47.58 115.43 45.68 
TARS 1.66 4.27 8.80 4.12 
TMX2-CTNND1 0.41 0.97 2.83 1.12 
C12orf59 0.25 1.44 4.13 0.60 
CEACAM1 17.36 84.28 181.43 35.52 
MAP2K6 0.27 1.28 4.32 0.59 
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Table 4.27. List of 18 genes that were upregulated by GM-CSF or R848. However, the 
combined effect of the two stimuli was less than that observed with R848 effect alone 
indicating that GM-CSF partially inhibited R848-induced effect. The fold change cut off for 
expression data in all comparisons was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ASB2 0.19 6.66 0.77 3.21 
ATF3 0.40 8.52 0.81 3.03 
BTG3 0.26 22.79 0.69 10.98 
C20orf118 0.74 13.99 1.71 3.70 
CCL18 0.03 21.69 0.42 5.43 
CCL2 0.30 64.84 4.10 8.82 
DDX60L 16.17 418.19 87.54 203.80 
GPR35 0.20 2.78 0.46 1.08 
KCNH4 2.51 35.09 5.33 12.71 
LAMP3 0.56 51.75 1.65 9.55 
LIMS1 9.09 334.43 33.14 72.86 
LIMS3 3.12 92.16 13.09 35.63 
NR4A1 0.31 5.67 0.96 2.23 
PLSCR1 7.17 505.74 95.25 242.59 
SAMHD1 8.05 267.08 28.23 77.30 
SMAD3 0.75 29.79 2.00 14.50 
SPATC1 0.11 19.16 1.35 7.58 
TFEC 0.66 167.54 2.63 53.75 
 
Table 4.28. List of 11 R848-upregulated genes that were downregulated by the combined 
treatment of R848 and GM-CSF. Genes’ level was increased by GM-CSF alone, but GM-CSF 
inhibited further induction of the genes by R848. The fold change cut off for expression data 
in all comparisons was 2-fold in both directions. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ARHGAP24 0.12 3.23 1.40 0.91 
C5orf58 0.54 5.46 1.98 1.78 
CYBB 20.65 353.70 161.16 168.07 
DYNLT3 5.15 43.73 12.09 19.74 
GNG10 44.65 136.84 93.72 65.08 
LGALS8 2.68 7.72 5.84 3.35 
LMNA 0.17 1.70 0.48 0.55 
MILR1 2.44 13.54 5.96 5.44 
RFX5 2.62 10.47 8.15 5.00 
TLR4 84.78 298.97 175.11 144.13 
TRIM22 44.82 499.28 97.53 113.51 
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Table 4.29. List of a selection of R848-upregulated genes (248) that were downregulated by 
the addition of GM-CSF. The genes were not differentially regulated by GM-CSF alone. The 
fold change cut off for expression data in all comparisons was 2-fold. Majority of genes in this 
category are IFN-response genes. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
BIRC2 37.03 191.92 36.81 86.80 
CYBA 379.26 1527.56 430.50 694.34 
DMXL2 7.76 248.47 7.36 113.86 
EIF2AK2 6.17 220.04 5.35 62.64 
FAM129A 75.45 328.99 79.74 159.49 
GAPT 83.65 641.69 84.88 241.24 
GNB4 19.01 40.44 17.58 17.47 
GTPBP2 11.33 79.50 11.43 33.02 
HIF1A-AS2 126.25 610.39 143.31 175.60 
IFI6 50.76 1295.02 50.87 262.31 
LGALS9 33.42 82.45 30.51 23.70 
OAS3 6.12 499.06 6.11 187.54 
ORM2 1.52 70.27 1.26 12.46 
PARP12 10.09 101.55 8.93 39.42 
PARP9 25.80 307.15 20.87 95.26 
PLAC8 4.18 43.13 3.89 11.43 
SAMD9 44.58 290.02 36.44 70.44 
SP110 63.29 248.17 72.22 100.64 
SRC 1.03 77.48 1.17 19.87 
STAT2 16.82 201.23 20.09 71.77 
TRAFD1 27.94 61.62 27.82 18.91 
TRIM5 10.03 75.41 10.47 18.95 
UBL3 29.14 69.04 30.52 23.41 
  
Table 4.30. List of 5 GM-CSF-upregulated genes that were downregulated by the addition of 
R848 although R848 alone induced their expression. R848 or GM-CSF-induced expression 
was reverted back to the basal level in untreated (UT) cells by their combined effect. The fold 
change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
MB21D1 2.09 7.03 10.76 2.82 
RPL21 0.05 19.76 16.71 0.03 
SSB 1.62 5.27 5.92 2.31 
TGM2 12.50 113.24 60.29 21.74 
TXNIP 336.38 807.82 873.32 288.71 
 
  
 23 
Table 4.31. List of a selection of GM-CSF-upregulated (129) genes that were downregulated 
by the treatment with R848 and GM-CSF. The genes were not differentially regulated by R848 
alone, but R848 reduced their expression to the basal level in unstimulated (UT) cells The fold 
change cut off for expression data in all comparisons was 2-fold.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ABCG1 13.61 14.11 36.36 15.35 
BCL9 0.97 0.90 10.28 1.19 
C1RL 9.08 7.32 34.13 9.33 
C4orf3 12.24 13.13 53.89 14.70 
DDAH2 22.41 27.92 49.97 20.51 
EIF4G3 7.71 6.49 15.62 6.69 
F2R 2.86 2.39 11.68 2.56 
FKBP1A 129.21 131.35 276.55 135.67 
IL18RAP 7.57 8.73 39.62 8.12 
IL1RAP 63.81 53.78 254.57 51.03 
IRF2BP2 49.44 50.54 193.03 49.30 
KLF2 41.12 45.88 107.88 45.41 
NOTCH2 36.43 50.15 86.69 42.02 
RGS3 5.44 6.61 18.20 4.92 
RNF141 34.63 28.42 120.09 28.49 
SWAP70 7.64 6.47 16.50 6.25 
TSPAN14 32.61 34.55 67.96 29.53 
TUBA1C 16.67 14.10 45.39 12.93 
TUBB 29.12 23.87 82.65 39.39 
 
Table 4.32. List of some GM-CSF-upregulated genes (47) that were downregulated by the 
treatment with R848 and GM-CSF. The genes were not differentially regulated by R848 alone, 
but R848 partially reduced their expression compared to GM-CSF-induced effect. to less than 
the basal level in unstimulated (UT) cells The fold change cut off for expression data in all 
comparisons was 2-fold.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ANXA3 3.05 5.79 50.10 24.38 
C6orf97 0.52 1.00 13.06 3.08 
CBWD1 1.06 2.03 6.40 2.65 
HRH4 0.84 1.62 181.42 18.97 
ITGAM 54.12 78.35 315.06 139.99 
NUBP1 0.87 1.25 22.62 9.26 
PER2 0.91 1.69 13.14 2.68 
POU5F1P3 3.89 5.48 52.80 18.54 
RMND1 0.91 1.65 10.55 4.72 
SERTAD2 8.63 13.02 103.98 46.53 
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Table 4.33. List of 7 GM-CSF-upregulated genes that were partially downregulated by the 
treatment with R848 and GM-CSF compared to untreated cells. The expression of the genes 
was decreased by the effect of R848 alone. The fold change cut off for expression data in all 
comparisons was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ACAA2 1.07 0.44 9.94 4.52 
CISH 2.35 0.76 573.28 207.68 
FLT3LG 1.96 0.37 10.86 5.35 
SNTB1 0.81 0.23 12.08 4.56 
SORT1 2.76 0.50 40.46 10.16 
STEAP4 30.47 6.41 551.15 116.37 
TGFA 8.30 2.01 64.33 20.47 
 
Table 4.34. List of 12 genes with reduced expression by R848. All genes were upregulated by 
GM-CSF alone. However, the combined treatment of R848 and GM-CSF was similar to that 
induced by GM-CSF alone indicating that GM-CSF stopped the downregulatory effect of 
R848. The fold change cut off for expression data in all comparisons was 2-fold in both 
directions.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ACSS2 11.80 1.51 52.24 30.69 
CAMK1D 17.57 8.44 50.51 28.87 
CD300C 3.52 1.68 10.51 5.38 
GALNT2 4.06 1.15 12.26 8.73 
HSPA1A 31.40 13.17 80.10 72.10 
HSPA1B 21.08 9.18 59.78 53.34 
LOC100506963 2.19 0.72 4.48 4.11 
NUDT5 6.89 2.94 62.82 34.15 
RRP12 2.53 0.81 10.57 8.72 
SUMF1 2.18 0.72 4.96 3.44 
TSTA3 6.67 3.11 14.62 9.24 
USP32 33.97 15.30 81.20 48.63 
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Table 4.35. List of selected GM-CSF-upregulated genes (68 in total) that were downregulated 
by pretreatment with R848 to the basal expression level in untreated cells. The expression of 
the genes was decreased by the effect of R848 alone. The fold change cut off for expression 
data in all comparisons was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
BST1 29.76 13.06 90.29 24.59 
CCND3 25.56 8.26 104.23 20.12 
CTSC 94.48 30.06 611.55 110.54 
HIATL1 13.41 6.50 31.60 10.82 
KIAA0040 21.94 5.53 219.57 18.98 
KIF21B 9.19 3.14 28.94 7.72 
LOC283070 10.51 2.99 26.27 12.25 
MAPKAPK3 37.73 4.97 185.38 27.04 
PRDX3 6.44 2.79 14.47 4.53 
PTEN 51.51 20.30 137.31 37.55 
PTENP1 11.53 4.55 35.06 10.24 
SNX17 7.19 3.33 14.51 5.92 
WDR37 8.26 2.57 18.09 7.53 
 
Table 4.36. List of selected GM-CSF-upregulated genes (69 in total) that were downregulated 
by pretreatment with R848 to less than the basal expression level in untreated cells. Expression 
of genes was decreased by the effect of R848 alone. Fold change cut off for expression data in 
all comparisons was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
AFF1 18.85 9.40 43.54 7.81 
CAB39 62.14 25.43 233.62 28.48 
CMTM1 20.10 7.92 61.90 9.36 
GLIPR2 86.05 23.73 213.92 30.28 
LPIN2 88.00 15.74 219.95 13.34 
LTA4H 43.57 6.48 231.93 11.82 
MYADM 98.94 16.77 206.30 18.68 
P2RY13 198.60 31.45 437.99 40.27 
PGAM1 29.39 6.74 59.36 11.21 
PIK3CD 83.56 28.69 181.00 35.79 
PPM1M 33.35 7.22 71.60 8.42 
PYCARD 98.70 14.88 219.41 29.74 
STK17B 43.02 15.32 86.86 9.69 
TSPO 65.14 9.01 150.40 13.16 
TUBA1A 48.38 5.68 122.50 7.69 
TUBA1B 28.69 9.08 84.34 10.38 
TWF2 64.37 17.22 131.03 14.26 
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Table 4.37. Genes that were reduced by GM-CSF. Their expression was increased by R848 
alone. GM-CSF either partially diminished the upregulatory effect of R848 (15 genes,top 
group) or had no effect on R848-induced expression (9 genes, bottom group). The fold change 
cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
CMPK2 2.51 220.22 1.18 38.26 
DDX58 25.14 217.55 12.10 58.22 
DUSP16 6.07 45.96 2.48 15.08 
FSCN1 2.55 12.48 1.22 5.61 
HERC5 7.78 349.25 2.42 37.27 
IFI44 4.44 147.60 1.95 25.21 
IFIT1 23.46 1249.30 8.62 186.02 
MT2A 12.77 241.92 5.04 67.40 
MX2 79.53 650.57 33.39 206.88 
OAS1 5.04 109.77 1.73 22.58 
PTGES 7.10 488.59 0.96 46.30 
TCFL5 2.70 211.85 0.82 85.86 
IFIT1B 0.56 22.42 0.17 2.87 
KIAA1045 0.47 3.22 0.09 1.24 
MARCH3 0.97 12.34 0.32 3.29 
BCL9L 2.49 10.03 0.65 8.54 
BMF 5.12 16.31 2.35 10.96 
CLEC4E 64.15 509.90 30.35 334.33 
SLC7A7 9.96 196.48 4.60 191.63 
TECPR2 16.41 40.80 7.59 40.81 
GRAMD1A 32.39 471.13 15.25 315.20 
HMGN2P46 4.86 12.19 1.33 11.58 
LPCAT1 160.02 554.34 65.44 368.33 
PLAUR 251.99 1435.37 89.39 905.31 
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Table 4.38. List of 32 genes that were downregulated by GM-CSF. The expression of the genes 
was increased by R848 alone. GM-CSF completely inhibited the upregulatory effect of R848 
and their levels were similar to that of the untreated cells. The fold change cut off for expression 
data in all comparisons was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ANXA6 1.52 5.20 0.73 1.78 
AOAH 20.10 50.22 3.95 18.41 
APOL3 1.31 4.75 0.42 0.97 
C1GALT1 9.43 45.63 3.22 7.56 
CADM4 6.90 17.19 1.53 7.30 
COL9A3 2.58 9.82 0.58 3.15 
DNAJB5 0.99 4.80 0.22 1.39 
GBP1 34.95 323.58 11.41 49.95 
GBP1P1 3.19 32.25 1.09 5.40 
GBP3 4.41 40.45 2.06 6.78 
GBP4 31.57 130.32 5.68 15.65 
GBP7 0.90 4.14 0.12 0.56 
IFIT2 211.35 2279.85 74.69 269.75 
LIF 1.28 6.17 0.35 1.21 
LOC100132707 1.37 4.51 0.23 2.12 
JAG1 2.96 10.27 1.44 5.55 
MEPCE 17.79 40.12 7.76 18.28 
OASL 21.35 222.58 4.51 36.87 
OTUD5 43.76 97.28 20.76 72.94 
PDE4A 0.68 2.65 0.33 0.97 
PDE8A 2.51 5.96 0.93 2.90 
PLXNC1 101.79 274.68 43.69 128.73 
RNF144A 1.87 5.12 0.73 1.91 
SELK 32.80 77.09 10.01 51.03 
SERPING1 2.42 7.84 1.20 2.54 
SGMS1 3.28 10.03 0.74 3.46 
SIN3A 7.29 16.51 2.97 12.01 
SSBP3 3.97 11.25 1.95 5.29 
SLC25A39 1.40 4.64 0.56 1.45 
STAT5A 23.80 63.10 8.11 38.48 
TMEM123 54.57 364.77 19.27 64.54 
TP53INP2 34.18 90.32 11.32 46.86 
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Table 4.39. List of selected GM-CSF-downregulated genes (28 in total) that were returned to 
the basal level of gene expression in untreated cells by the effect of R848. R848 alone had no 
effect on these genes. The fold change cut off for expression data in all comparisons was 2-
fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
AATK 40.04 51.54 16.60 34.97 
ACD 5.90 3.24 1.19 5.06 
BASP1 324.44 535.68 87.68 202.12 
C7orf53 16.89 12.34 6.69 16.70 
CABLES2 2.61 4.42 0.51 2.51 
CERS4 5.51 6.37 1.45 3.16 
CHD4 16.68 28.62 8.12 21.02 
CHRNA10 2.72 2.77 0.80 2.28 
FAM134B 2.12 2.47 0.74 2.60 
FOXP1 3.14 3.36 1.06 3.70 
GPR137 2.48 2.70 0.88 2.26 
GPR157 3.77 3.58 0.89 3.34 
HSH2D 85.19 148.10 21.18 50.67 
NCOA4 220.92 240.50 59.12 144.35 
NR4A2 2.50 2.34 0.63 2.79 
RAD9A 9.76 8.90 4.34 10.38 
REPS2 7.62 10.51 2.57 6.43 
RNU6ATAC 16.56 26.77 7.97 20.79 
SIPA1L1 24.39 24.64 9.70 19.60 
SLC37A1 4.39 3.09 1.23 2.91 
STX5 16.74 21.63 7.48 19.15 
TESK2 5.23 9.68 1.19 3.78 
TFDP1 30.36 50.23 8.69 24.81 
TMEM8A 28.83 33.23 11.05 23.56 
UBR7 3.06 1.66 1.17 2.78 
VPS13D 3.04 3.74 1.52 3.41 
WDFY1 12.66 18.29 4.61 11.60 
ZSCAN16 5.43 9.04 1.19 3.28 
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Table 4.40. A selection of GM-CSF-downregulated genes (136) that were additively inhibited 
by the combined effect of R848 and GM-CSF. R848 alone reduced the expression of these 
genes. The fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ABHD2 126.68 22.00 27.61 8.08 
AMPD2 281.33 51.57 81.23 15.66 
BTG1 265.07 76.63 57.22 27.37 
BTN3A1 104.50 20.70 27.10 8.25 
C14orf159 48.91 10.72 14.59 3.51 
CCNG2 89.78 15.89 13.31 4.22 
CDKN1B 122.62 11.27 44.36 2.95 
CXCR2 665.42 31.11 168.04 13.47 
FCGR3A 621.82 143.48 218.89 60.09 
FCGR3B 1287.33 303.13 448.65 119.29 
FGL2 109.93 15.76 47.26 4.81 
HIST1H2AC 211.50 29.66 94.78 10.92 
INPP5D 159.58 43.34 60.16 17.85 
LPGAT1 44.86 12.95 18.92 5.97 
MKL1 66.00 11.69 23.25 4.61 
MNDA 587.22 160.98 262.18 80.16 
NUP50 81.03 18.23 37.55 6.82 
PHF12 38.92 10.13 17.68 2.58 
RERE 56.35 13.66 21.23 1.25 
RGS2 742.35 72.00 195.59 34.55 
TLR8 52.82 14.37 16.14 6.61 
TM6SF1 78.77 18.51 35.39 5.57 
TMEM66 385.63 47.07 101.52 22.91 
 
Table 4.41. GM-CSF-downregulated genes (9) that were additively inhibited by the combined 
effect of R848 and GM-CSF. R848 alone had no effect on the expression of these genes. The 
fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
C7orf70 12.50 8.38 4.53 1.66 
DCLRE1C 5.34 4.65 2.43 1.12 
GPR160 86.64 57.69 30.89 10.80 
IPMK 23.86 18.24 10.77 3.53 
PCMTD1 33.69 28.45 16.13 7.54 
RNF138 12.31 10.78 5.53 2.11 
SPOPL 52.38 32.76 22.19 8.00 
TRAF3IP3 41.83 34.07 19.10 6.07 
TRANK1 95.83 93.92 33.05 14.31 
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Table 4.42. List of some GM-CSF-downregulated genes (165) that were further inhibited by 
R848. The joined influence of R848 and GM-CSF was comparable to R848 effect alone. The 
fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
AKT1 73.01 10.98 35.46 9.79 
CXCR1 362.03 14.29 85.81 9.60 
DEF8 64.50 3.69 31.03 3.01 
FKBP8 120.56 23.37 59.62 19.16 
HMGN2 90.74 12.96 33.89 12.42 
ITGAL 33.41 6.81 16.19 6.20 
MPPE1 35.68 3.46 12.66 3.50 
NOTCH1 88.32 21.62 42.66 18.19 
PACS1 46.20 2.46 14.17 2.52 
RNASE6 158.26 3.27 25.92 2.80 
SLBP 31.80 1.25 14.73 1.25 
SRPK2 42.47 1.57 10.39 1.38 
TACC3 48.11 1.56 20.76 1.29 
TBC1D10C 51.50 2.83 20.14 2.39 
 
Table 4.43. List of 18 genes that were upregulated by R848. All genes were downregulated by 
GM-CSF. However, the combined treatment of R848 and GM-CSF was lower than the basal 
level in untreated (UT) neutrophils. The fold change cut off for expression data in all 
comparisons was 2-fold in both directions.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ARL15 2.53 5.36 0.57 0.51 
BMPR2 0.95 2.17 0.29 0.37 
CUX1 12.68 30.35 5.20 3.49 
CYFIP2 50.56 127.26 14.66 15.45 
EXOC3L1 0.69 2.48 0.11 0.21 
FAM8A1 46.67 128.53 17.98 17.08 
GBP5 104.51 218.21 50.95 98.23 
GM2A 2.61 13.84 0.99 1.88 
LOC100861402 0.81 2.19 0.39 0.46 
MAK 2.80 6.44 1.38 2.25 
PIGF 34.12 77.51 16.55 14.47 
RALGAPA1 9.20 27.31 3.55 6.87 
SH3D21 9.69 25.65 4.17 7.99 
SIGLEC10 159.78 370.09 55.52 80.44 
SIGLEC11 5.97 12.00 2.53 2.93 
STX17 2.87 7.07 1.25 1.65 
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Table 4.44. A selection of 56 genes that were downregulated by R848. GM-CSF and the 
combined treatment had no effect on these genes indicating that GM-CSF completely stopped 
the downregulatory effect of R848. The fold change cut off for expression data in all 
comparisons was 2-fold in both directions.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ARRB2 381.09 178.63 493.90 397.27 
BCYRN1 13.13 4.70 13.61 11.43 
COX5A 6.38 1.77 6.36 4.75 
INTS8 15.01 4.30 19.85 20.82 
MFNG 82.42 19.24 73.50 67.66 
PITPNC1 14.67 5.60 27.56 20.97 
PPP1R35 14.05 5.19 14.35 10.81 
PSD4 67.14 26.53 78.88 56.33 
XRN2 18.29 7.86 25.04 23.72 
 
Table 4.45. List of some R848 -downregulated genes (46 in total) that were further inhibited 
by combined treatment of R848 and GM-CSF. The joined influence of R848 and GM-CSF was 
comparable to GM-CSF downregulatory effect indicating that GM-CSF masked R848 effect. 
The fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ALG1L2 13.89 4.43 3.09 1.87 
BAD 6.38 2.14 1.49 0.91 
CCDC28A 34.49 6.68 4.09 2.73 
CPNE3 7.38 3.35 2.16 1.30 
DCAF15 13.42 5.60 4.07 2.69 
FAM118A 16.48 3.85 1.33 0.91 
FRY 17.19 4.11 1.93 1.75 
MEGF9 83.13 39.30 10.87 9.43 
NUMA1 22.91 8.59 4.41 3.18 
PLOD1 11.41 4.22 1.25 0.84 
SMC4 7.67 2.79 1.69 1.25 
ST6GALNAC2 25.52 4.98 2.49 1.89 
TMEM63A 5.41 2.69 1.71 1.29 
UCK1 6.78 2.91 2.15 1.35 
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Table 4.46. A selection of 30 genes that were downregulated by R848. GM-CSF alone had no 
effect on these genes, but it partially inhibited the downregulatory effect of R848. The fold 
change cut off for expression data in all comparisons was 2-fold in both directions.  
	
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ATP2A3 93.11 8.79 103.78 22.82 
BCKDHA 5.36 1.20 8.79 2.55 
CMTM2 85.21 11.10 118.69 22.65 
CNPPD1 25.60 4.83 33.27 10.60 
DUSP23 6.71 0.96 7.02 2.50 
ERICH1 5.26 1.20 6.86 2.54 
FAM101B 29.10 4.38 37.74 12.53 
MINK1 13.43 2.35 19.68 8.92 
MLX 18.12 5.86 26.82 11.96 
MMP25 207.35 12.09 180.08 27.40 
NAPRT1 28.06 6.47 40.84 18.12 
PGM2 7.68 1.16 11.89 4.10 
PMF1 6.33 1.00 10.18 2.17 
RALBP1 37.65 3.24 31.50 14.89 
RNF220 5.87 1.36 8.62 3.80 
SLC19A1 57.22 5.30 64.56 10.98 
THBD 25.23 3.82 32.00 9.61 
TMC6 34.38 1.77 29.22 7.40 
TMEM65 10.10 1.17 10.88 2.51 
 
Table 4.47. List of selected R848 -downregulated genes (91 in total) that were further inhibited 
by the combined treatment of R848 and GM-CSF. GM-CSF alone had no effect on their 
expression, but it augmented R848-induced effect. The fold change cut off for expression data 
was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
C10orf54 213.24 45.30 193.09 12.52 
CEACAM21 18.76 2.74 15.47 1.02 
CLEC2B 97.15 44.62 101.32 20.95 
EVI2B 450.08 86.82 462.89 39.46 
FLI1 72.87 14.15 75.93 6.75 
PHF23 21.70 8.87 17.77 4.22 
RSBN1L 27.77 6.56 22.78 1.65 
SETD1B 27.79 5.93 22.71 2.21 
TSEN34 27.95 3.10 27.12 1.50 
ZNF217 67.65 24.99 65.59 11.85 
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Table 4.48. Genes downregulated by R848 or GM-CSF. However, the combined treatment of 
R848 and GM-CSF was similar to that induced by GM-CSF alone indicating that GM-CSF 
prevented R848-induced effect. The fold change cut off for expression data in all comparisons 
was 2-fold in both directions.  
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
HMGB1 48.86 11.24 24.15 22.92 
TP53INP1 110.33 18.60 37.75 43.27 
 
Table 4.49. List of selected genes (397 in total) that were not differentially regulated by R848 
or GM-CSF. However, the combined treatment with R848 and GM-CSF reduced their 
expression. The fold change cut off for expression data was 2-fold. 
 
Gene UTFPKM R848FPKM GM-CSFFPKM R848+GM-CSFFPKM 
ATP7A 14.10 11.27 11.36 6.15 
CMIP 46.98 36.54 35.30 20.83 
CSGALNACT1 11.62 13.01 14.31 4.15 
DCAF12 21.90 17.10 26.39 8.97 
GLRX 102.56 86.69 84.39 33.58 
IRF1 92.67 132.39 85.46 33.07 
ISCU 70.47 70.21 56.82 34.73 
LSP1 641.83 548.49 581.96 310.23 
PIK3CA 17.93 15.46 16.60 8.53 
PLEKHO1 116.49 93.86 106.90 47.92 
PSMB9 92.79 104.39 98.99 40.43 
RAB27A 27.60 23.25 37.79 12.88 
RNASEL 24.25 22.89 26.72 10.83 
RUNX3 10.02 12.63 10.76 4.39 
SLA 176.51 200.82 133.17 78.18 
SLC12A6 102.53 107.00 114.48 0.00 
SNX13 14.97 12.71 12.13 6.59 
TP53I11 19.35 15.71 19.36 6.54 
USF1 65.35 59.12 53.10 25.70 
 
